1. Home
  2. TTRX vs GLED Comparison

TTRX vs GLED Comparison

Compare TTRX & GLED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

HOLD

Current Price

$8.54

Market Cap

281.2M

Sector

Health Care

ML Signal

HOLD

GLED

GalaxyEdge Acquisition Corporation Ordinary Shares

N/A

Current Price

$9.97

Market Cap

159.0M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
TTRX
GLED
Founded
2015
N/A
Country
United States
Employees
2
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
281.2M
159.0M
IPO Year
N/A
2026

Fundamental Metrics

Financial Performance
Metric
TTRX
GLED
Price
$8.54
$9.97
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$8.00
N/A
AVG Volume (30 Days)
124.9K
69.2K
Earning Date
05-31-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.57
$9.94
52 Week High
$11.69
$9.98

Technical Indicators

Market Signals
Indicator
TTRX
GLED
Relative Strength Index (RSI) 55.17 58.33
Support Level $8.51 $9.95
Resistance Level $11.69 $9.98
Average True Range (ATR) 1.12 0.00
MACD -0.10 0.00
Stochastic Oscillator 27.11 75.00

Price Performance

Historical Comparison
TTRX
GLED

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

About GLED GalaxyEdge Acquisition Corporation Ordinary Shares

GalaxyEdge Acquisition Corp is a newly organized blank check company. The company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities.

Share on Social Networks: